Compare BRO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRO | BIIB |
|---|---|---|
| Founded | 1939 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.6B | 24.2B |
| IPO Year | N/A | 1991 |
| Metric | BRO | BIIB |
|---|---|---|
| Price | $73.78 | $201.18 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 24 |
| Target Price | $89.54 | ★ $181.77 |
| AVG Volume (30 Days) | ★ 3.1M | 1.6M |
| Earning Date | 01-26-2026 | 02-06-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 3.16 | ★ 10.97 |
| Revenue | $5,763,000,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | $28.13 | $3.60 |
| Revenue Next Year | $7.07 | N/A |
| P/E Ratio | $23.00 | ★ $16.89 |
| Revenue Growth | ★ 22.30 | 4.77 |
| 52 Week Low | $70.45 | $110.04 |
| 52 Week High | $125.68 | $190.20 |
| Indicator | BRO | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 40.13 | 64.98 |
| Support Level | $70.45 | $176.19 |
| Resistance Level | $75.28 | $187.73 |
| Average True Range (ATR) | 2.17 | 4.55 |
| MACD | -0.31 | 1.43 |
| Stochastic Oscillator | 27.91 | 98.43 |
Brown & Brown Inc is a diversified insurance agency, wholesale brokerage, insurance programs, and service. The Company markets and sells insurance products and services, in the property, casualty, and employee benefits areas. It provides customers with non-investment insurance contracts, as well as other targeted, customized risk management products and services. It has four reportable segments; the Retail segment; the Programs segment; the Wholesale Brokerage segment and; the Services segment. It generates the majority of its revenue from the Retail segment which provides insurance products and services to commercial, public and quasi-public, and Others through automobile dealer services F&I businesses. Its geographic area is U.S., U.K., the Republic of Ireland, Canada, and Others.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).